New test may predict prostate cancer treatment success
NCT ID NCT07112612
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a test called minimal residual disease (MRD) can help predict how well treatment works in men with metastatic hormone-sensitive prostate cancer. Researchers will track 50 newly diagnosed patients to see how different gene patterns affect treatment response. The goal is to make treatment more personalized and precise.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MHSPC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?